

	DISCOVERY			TRANSLATION			DEVELOPMENT		IMPLEMENTATION	
	Screen	Hit-to-lead	Lead optimization	Pre-clinical	Phase I	Phase IIa/ Proof-of-concept	Phase IIb/III	Registration	Treatment access	
<b>SLEEPING SICKNESS</b>							Acoziborole <sup>+</sup>		Fexinidazole for <i>T.b.gambiense</i> * <sup>+</sup>	
							Fexinidazole for <i>T.b. rhodesiense</i> <sup>+</sup>		Nifurtimox-eflornithine combination therapy (NECT)*	
<b>LEISHMANIASIS</b>	Screening	Hit-to-lead	S07 series <sup>+</sup>	DNDI-6174 <sup>+</sup>	DNDI-6148 <sup>+</sup>		New CL combination	New VL treatments (Latin America)	SSG&PM (East Africa)*	
		NTD Drug Discovery Booster Hit-to-lead	CF series <sup>+</sup>		DNDI-0690 <sup>+</sup>		New treatments for PKDL		New treatments for HIV/VL	New VL treatments (South Asia)*
					GSK899 DDD853651 <sup>+</sup>		Miltefosine + paromomycin combination (Africa)			
					LXE408 Novartis <sup>+</sup>					
					CpG-D35 for CL <sup>+</sup>					
					GSK245 DDD1305143 <sup>+</sup>					
<b>CHAGAS DISEASE</b>	Screening	Hit-to-lead	UW series <sup>+</sup>	Biomarkers	DNDI-6148 <sup>+</sup>	Fexinidazole <sup>+</sup>	New benznidazole regimens <sup>+</sup>		Benznidazole paediatric dosage forms*	
		NTD Drug Discovery Booster Hit-to-lead	Daiichi Sankyo series <sup>+</sup>							
<b>FILARIA: RIVER BLINDNESS</b>				CC6166 <sup>+</sup>	Oxfendazole <sup>+</sup>	Emodepside <sup>+</sup>				
						TylAMac (ABBV-4083) <sup>+</sup>				
<b>MYCETOMA</b>							Fosravuconazole <sup>+</sup>			
<b>HIV</b>					5 FC (cryptococcal meningitis)			4-in-1 (ABC/3TC/LPV/r)	Super-booster for children with HIV/TB*	
									2-in-1 LPV/r pellets	
									5 FC, LamB access (crypto meningitis)	
<b>HEPATITIS C</b>							Ravidasvir + sofosbuvir <sup>+</sup>		Ravidasvir* and other DAAs <sup>+</sup>	
<b>COVID 19/ Pandemic Preparedness</b>		Broad-spectrum antivirals Hit-to-lead	TMEM16 series	Pre-clinical support			ANTICOV			
			Moonshot							
<b>MALARIA</b> ★									Fixed-dose combination ASMQ*	
									Fixed-dose combination ASAQ*	

★ Implementation transferred to the Medicines for Malaria Venture in 2015

<sup>+</sup> NCE (New chemical entity)

\* Treatments delivered by DNDi with partners

▶ Treatments not delivered by DNDi, but DNDi working on access